Topic overview
Briefly
- Reckitt faces a US courtroom showdown over baby formula claims.
- The lawsuit alleges Mead Johnson failed to warn parents about NEC risk.
- Reckitt denies the claims, citing science and medical consensus.
What happened
Consumer goods giant Reckitt is set to face a US courtroom showdown tomorrow in the latest round of a class action lawsuit connected to its baby formula products. The litigation, which is due to begin in the US district court in Illinois, involves hundreds of lawsuits consolidated into a single class action. The plaintiffs allege that one of Reckitt's subsidiaries, Mead Johnson, failed to warn parents that its infant milk formula Enfamil raised the risk of developing necrotising enterocolitis (NEC), a bowel condition that is often fatal in newborn and premature infants. Reckitt denies the claims, stating that the science and medical consensus do not support the allegations. The company has previously faced similar lawsuits, and last month a jury in Missouri rejected claims that Mead Johnson's formula was responsible for an infant's NEC. However, an Illinois court in June reversed a $60 million verdict against the firm, which had been found liable for failing to warn parents. The lawsuits have weighed on Reckitt's share price, which has fallen nearly 13 per cent over the past five years as investors fret about potential costs. The bellwether trial is seen as a pivotal moment for the families affected by NEC, according to Sara Papantonio at Levin Papantonio, the law firm representing the plaintiffs. Reckitt remains confident in its position and looks forward to presenting its case at trial. The outcome of this trial could have significant implications for the company and the broader baby formula industry, as similar allegations are also pending against Abbott Laboratories, the maker of Similac. The trial is expected to set a precedent for the hundreds of other lawsuits that have been consolidated, and a ruling against Reckitt could lead to substantial financial damages and potentially force changes in how infant formulas are marketed and labeled. Conversely, a victory for Reckitt could bolster its defense in other cases and reassure investors. The case highlights the ongoing legal battles over the safety of infant formula products and the responsibility of manufacturers to warn consumers about potential risks. The trial is scheduled to begin tomorrow, and the outcome will be closely watched by the industry, legal experts, and families affected by NEC.
Comprehensive report
Full story,
in detail.
Trace the developments that led here, see how the story evolved, and understand the forces and wider context surrounding it.